a Department of Otorhinolaryngology Head and Neck Surgery , Aarhus University Hospital , Aarhus , Denmark.
b Department of Otorhinolaryngology Head and Neck Surgery , Regionshospitalet Holstebro HEV , Holstebro , Denmark.
Infect Dis (Lond). 2017 Nov-Dec;49(11-12):792-798. doi: 10.1080/23744235.2017.1342142. Epub 2017 Jun 23.
Necrotizing fasciitis in the head and neck (NF-HN) is a rare and potentially life-threatening condition. The use of hyperbaric oxygen therapy (HBOT) in the acute regimen is disputed and there is a lack of evidence of therapeutic effect. This study aims to describe a retrospective cohort of patients with NF-HN and investigate the use of HBOT and consequences thereof.
All patients treated for NF-HN at Aarhus University Hospital (AUH) between 2002 and 2014 were included in this retrospective cohort. Data regarding demographics, treatment and a one-year follow-up was registered. A review of the literature on NF-HN and HBOT was performed.
Forty-three patients were consecutively treated for NF-HN during the period. All patients were treated in accordance with current guidelines with HBOT as a variable. Thirty patients received HBOT, and 13 patients were omitted from HBOT for different reasons. In the HBOT group were no mortalities vs. three mortalities in the non-HBOT group two late deaths due to precursory underlying cancer of the head and neck, and one early death shortly after admittance. We found higher rates of complications (63% vs. 25%) and sequelae (77% vs. 40%) among the HBOT group compared to the non-HBOT group.
Our findings suggest that HBOT for NF-HN may only be optional and that the decision relies on an individual assessment of each patient. Further research is needed concerning the evidence of HBOT and towards selecting the patients benefitting from HBOT.
头颈部坏死性筋膜炎(NF-HN)是一种罕见且潜在威胁生命的疾病。在急性治疗方案中使用高压氧治疗(HBOT)存在争议,并且缺乏治疗效果的证据。本研究旨在描述一组 NF-HN 患者的回顾性队列,并探讨 HBOT 的使用及其后果。
纳入 2002 年至 2014 年在奥胡斯大学医院(AUH)接受 NF-HN 治疗的所有患者进行回顾性队列研究。记录了人口统计学、治疗和一年随访的数据。对 NF-HN 和 HBOT 的文献进行了综述。
在此期间,连续有 43 例患者因 NF-HN 接受治疗。所有患者均按照现行指南进行治疗,HBOT 为变量。30 例患者接受 HBOT,13 例患者因各种原因被排除在 HBOT 之外。HBOT 组无死亡病例,而非 HBOT 组有 3 例死亡,其中 2 例为头颈部先前存在的癌症,1 例为入院后不久死亡。与非 HBOT 组相比,HBOT 组的并发症发生率(63%对 25%)和后遗症发生率(77%对 40%)更高。
我们的研究结果表明,HBOT 治疗 NF-HN 可能只是可选的,并且决策取决于对每位患者的个体评估。需要进一步研究 HBOT 的证据,并针对选择受益于 HBOT 的患者进行研究。